Entera Bio Ltd banner

Entera Bio Ltd
NASDAQ:ENTX

Watchlist Manager
Entera Bio Ltd Logo
Entera Bio Ltd
NASDAQ:ENTX
Watchlist
Price: 1.2 USD 1.69%
Market Cap: $55m

Entera Bio Ltd
Total Receivables

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Entera Bio Ltd
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Entera Bio Ltd
NASDAQ:ENTX
Total Receivables
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Kamada Ltd
NASDAQ:KMDA
Total Receivables
$32.7m
CAGR 3-Years
-3%
CAGR 5-Years
4%
CAGR 10-Years
2%
Enlivex Therapeutics Ltd
NASDAQ:ENLV
Total Receivables
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Urogen Pharma Ltd
NASDAQ:URGN
Total Receivables
$33.1m
CAGR 3-Years
38%
CAGR 5-Years
36%
CAGR 10-Years
N/A
Pluri Inc
NASDAQ:PLUR
Total Receivables
$169k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
1%
M
Matricelf Ltd
TASE:MTLF
Total Receivables
₪443k
CAGR 3-Years
41%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Entera Bio Ltd
Glance View

Market Cap
55m USD
Industry
Biotechnology

Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of orally delivered large molecule therapeutics. The firm conducts clinical trials on its proprietary technology, which allows oral delivery of large molecules and biologics while enhancing their absorption in the gastrointestinal (GI) tract. Entera Bio Ltd's technology addresses the major problems of oral drug delivery of large molecule active pharmaceutical ingredients (APIs). Most large molecules cannot be administered orally as they are not readily absorbed by the gastrointestinal tract and are rapidly degraded by a myriad of enzymes and acids in the gastrointestinal tract. The Company’s proprietary technologies act synergistically to transport and protect large molecules. The firm develops drugs for hypoparathyroidism, osteoporosis and bone healing.

ENTX Intrinsic Value
0.04 USD
Overvaluation 97%
Intrinsic Value
Price $1.2

See Also

What is Entera Bio Ltd's Total Receivables?
Total Receivables
0 USD

Based on the financial report for Sep 30, 2025, Entera Bio Ltd's Total Receivables amounts to 0 USD.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett